All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
To help navigate the exciting content being presented at the EHA2023 Congress, the MPN Hub Steering Committee have provided their recommendations for the top abstracts to look out for in MPN.
Abstract |
Type |
Title |
Presenter |
S210 |
Oral presentation |
An open-label, global, phase 1b/2 study adding navtemadlin (NVTM) to ruxolitinib (RUX) in patients with primary or secondary myelofibrosis who have a suboptimal response to RUX |
John Mascarenhas |
S211 |
Oral presentation |
Efficacy and safety of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis and DIPSS low/intermediate-1 risk myelofibrosis: Updated results and genomic characteristics |
Harry Gill |
S212 |
Oral presentation |
A randomized double-blind phase 3 study of jaktinib versus hydroxyurea in patients with intermediate-2 or high risk myelofibrosis |
Yi Zhang |
S213 |
Oral presentation |
BMS-986158, a potent BET inhibitor, as monotherapy and in combination with ruxolitinib or fedratinib in intermediate- or high-risk myelofibrosis: Results from a phase 1/2 study |
Haifa Kathrin |
Abstract |
Type |
Title |
Presenter |
LB2710 |
Late breaking oral presentation |
Marina Kremyanskaya |
Subscribe to get the best content related to MPN delivered to your inbox